Literature DB >> 21051032

Antivenin-related serum sickness.

Chin-Yuan Huang1, Dong-Zong Hung, Wei-Kung Chen.   

Abstract

Serum sickness is a type III hypersensitivity reaction that occurs due to the deposition of excessive circulating immune complexes in patients treated with foreign proteins or haptens. Serum sickness induced by antivenin for snakebites has been frequently reported in the USA, but not in Taiwan. This difference may be due to the efficacy and dosage of antivenins administered to treat snakebites in Taiwan. We report a case presenting with serum sickness after receiving a total of 20 vials of polyvalent antivenin therapy for the treatment of snakebite. A 59-year-old male suffered from fever, headaches, polyarthritis, and diffused skin rash approximately 10 days after administration of the antivenin. The large dose of antivenin administered in this case might have been the cause of the development of serum sickness. Physicians should be aware of the potential for serum sickness in cases of large-dose antivenin use.
Copyright © 2010 Elsevier. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051032     DOI: 10.1016/S1726-4901(10)70117-9

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  3 in total

1.  Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient.

Authors:  Soo Youn Jun; Gi Mo Jung; Seong Jun Yoon; Yun-Jaie Choi; Woo Suk Koh; Kyoung Sik Moon; Sang Hyeon Kang
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

2.  [Surgical treatment of bites].

Authors:  D Saul; K Dresing
Journal:  Oper Orthop Traumatol       Date:  2018-09-12       Impact factor: 1.154

3.  The Protocol of Choice for Treatment of Snake Bite.

Authors:  Afshin Mohammad Alizadeh; Hossein Hassanian-Moghaddam; Nasim Zamani; Mitra Rahimi; Mohammad Mashayekhian; Behrooz Hashemi Domeneh; Peyman Erfantalab; Ali Ostadi
Journal:  Adv Med       Date:  2016-09-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.